Neoadjuvant and adjuvant end-points in health technology assessment in oncology-Reference-Cited by-同舟云学术

Neoadjuvant and adjuvant end-points in health technology assessment in oncology

Published:2021-04 Issue: Volume:147 Page:40-50
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Harbeck Nadia,Schneeweiss Andreas,Thuss-Patience Peter^ORCID,Miller Kurt,Garbe Claus,Griesinger Frank,Eberhardt Wilfried E.E.,Klussmann Jens P.,Wollenberg Barbara^ORCID,Grimm Marc-Oliver,Zander Thomas,Lüftner Diana^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference91 articles.

1. Palliative chemotherapy or best supportive care? A prospective study explaining patients’ treatment preference and choice;Koedoot;Br J Canc,2003

2. Clinical trial endpoints for the approval of cancer drugs and biologics, Guidance for Industry,2018

3. Guideline on the evaluation of anticancer medicinal products in man,2017

4. 1555O_PRMagnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe;Hwang;Ann Oncol,2018

5. Health technology assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland;Allen;Value Health,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models;Breast Cancer;2024-01-30

2. Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress;Frontiers in Oncology;2023-10-03

3. Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study;Translational Cancer Research;2023-06

4. An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology;Applied Health Economics and Health Policy;2023-02-27

5. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification;Annals of Oncology;2022-07